Dermatology & Plastic Surgery Institute Outcomes
Surgical Quality Improvement
Dermatology & Plastic Surgery Institute Outcomes
Dermatology & Plastic Surgery Institute Surgery ACS NSQIP Outcomes
January 1, 2021 – December 31, 2021
The American College of Surgeons National Surgical Quality Improvement Program (ACS NSQIP®) objectively measures and reports risk-adjusted surgical outcomes based on a defined sampling and abstraction methodology. These outcomes data reflect Cleveland Clinic’s Dermatology & Plastic Surgery Institute surgery ACS NSQIP performance benchmarked against 457 participating sites.
Dermatology & Plastic Surgery (457 Sites) | N | Observed | Expected |
---|---|---|---|
30 Day Morbidity | 347 | 4.90% | 5.44% |
Cardiac | 347 | 0.29% | 0.03% |
Pneumonia | 347 | 0.00% | 0.09% |
Unplanned Intubation | 347 | 0.00% | 0.01% |
Deep Vein Thrombosis (DVT) / Pulmonary Embolus | 347 | 0.58% | 0.38% |
Urinary Tract Infection (UTI) | 347 | 0.00% | 0.19% |
Surgical Site Infection (SSI) | 346 | 4.91% | 4.31% |
Sepsis | 347 | 0.86% | 0.38% |
Return to Operating Room (ROR) | 347 | 4.90% | 5.07% |
Readmission | 347 | 3.46% | 2.99% |
American College of Surgeons National Surgical Quality Improvement Program, 2022.
ACS NSQIP® Semiannual Report July 12, 2022, Chicago: American College of Surgeons.